ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

How Collaboration Is Driving the Next Wave of Genomics

By: 3BL Media

Illumina’s Open Innovation programs work with partners to change lives

SOURCE: Illumina

DESCRIPTION:

BY FASTCO WORKS

RESHAPING MEDICINE

Illumina’s advances in genetic sequencing are reshaping medicine. Genetic sequencing has now allowed cancer patients to find treatment options specific to their tumors, doctors to anticipate adverse drug reactions and personalize medicine, public health agencies around the world to track and detect new COVID variants, and patients with rare diseases to more easily identify and treat their illnesses.

A NETWORK OF INNOVATION

Through Illumina Open Innovation, Illumina is investing in new startups and partnering in research efforts to develop solutions in areas such as rapid sequencing and data security. “To really unlock the power of the genome is something we can’t do alone,” Van Zeeland says.

Read the full article here

Learn more about Illumina here

Tweet me: Learn about @illumina's Open Innovation program and how investments in new startups can create opportunities and innovations that are unlocking the power of the genome and ultimately reshaping medicine. Read the full story here: https://bit.ly/3xQxhoP

KEYWORDS: NASDAQ: ILMN, illumina, genomics, Genetic Sequencing, Cancer patients, Illumina Open Innovation, Ashley Van Zeeland

“Our open innovation and philanthropic efforts will make sure [that] transformative innovations are actually getting out and changing lives,” says Illumina VP Ashley Van Zeeland. Photography by Kristy Walker.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.